Revolutionizing infectious disease diagnosis
Covirabio GmbH is a young Start-Up company with the vision to enable pathogen detection and immune monitoring at the Point-of-Care or Point-of-Need. Based on the Covirabio technology platform VERB (Virus Entry Receptor Binding), a portfolio of test systems for the detection of SARS-CoV-2 infections or the immune response to an infection and/or vaccination is currently being developed. For the use at the Point-of-Care or Point-of-Need, the assays are integrated into microfluidic systems. This technology platform is now also expanded to bacterial pathogens.
For the development of diagnostic solutions, Covirabio is capitalizing on the highly specific host pathogen interactions. The integration of the bioassays into microfluidic solutions comes with multiple benefits such as the use at the Point-of-Care/Point-of-Need, cost-effective operation, and safe handling of biological samples in sealed chips.
The Virus Entry Receptor Binding Technology was developed for the SARS-CoV-2 corona virus at the peak of the pandemic to enable the isolation of intact and likely infectious viral particles that can bind to the human cell entry receptor ACE2. The assay is available in a lab-based format (VERB – RUO). For the incorporation into a microfluidic format a multinational consortium was formed.
Two point-of-care solutions for the monitoring of neutralizing antibodies based on the abolishment of host-pathogen interactions are currently developed by Covirabio in collaboration with SAICO biosystems and the Cell Chip Group at the Technical University Vienna. The projects are kindly supported by the Vienna Business Agency.
Magnetic beads functionalized with proteins involved in the host-pathogen interaction are developed for the enrichment and diagnosis of bacterial pathogens. Our collaborators of the Cell Chip Group at the Technical University Vienna and SAICO biosystems integrate the bioassay into microfluidic systems and develop a microfluidic assay for the determination of the pathogens phenotypic antibiotic susceptibility profile.
Our CEO Dr. Bernhard Klemen has been interviewed for the current BioNanoNet Quarterly issue! BNN Quarterly is a digital magazine for developments in sustainable technology and can be accessed online! Follow the link to read the latest issue!
Covirabio has been presented at the 5th BioNanoNet Member Welcome Webinar by Lead Scientific Advisor and Co-Founder Dr. Marko Poglitsch! The life webinar has been taking place on May 25th 09:00-10:00 CEST and the recording thereof can be accessed now online!
We have lanched a new application for our VERB (RUO) kit! Besides SARS-CoV-2 virus capture and immune monitoring can the kit also be used to detect SARS-CoV-2 spike protein! This counts up on already 3 established applications for our VERB kit!
VERB kit fulfils your research needs: capture of intact SARS-CoV-2 viral particles, detection of neutralizing antibodies and beyond
Covirabios VERB kit enables rapid capture of intact SARS-CoV-2 (all variants) from a variety of sample matrices, using ACE2 functionalized magnetic beads
The VERB kit also enables the determination of neutralizing antibody titer to study the statue of the immune responses in a BSL2 lab environment
This innovation using new ACE2-functionalized magnetic beads will strengthen the VERB platform’s leading role in intact viral particle capture and neutralizing antibody detection, helping to further research to combat the COVID pandemic
Vienna, Austria, October 10th, 2022- Covirabio, an innovative biotech company, announced the launch of the VERB kit of its Virus Entry Receptor Binding (VERB) Platform for studies on SARS-CoV-2 research. The new ACE2 functionalized magnetic beads enable reserchers to add capabilities in isolating all SARS-CoV-2 variants from a wide range of samples , as well as enabling research based on ACE2 binding ranging from neutralizing antibody detection, viral entry inhibitor screening, to spike protein purification.
The highly efficient binding of SARS-CoV-2 via its spike protein to its cellular entry receptor ACE2 - which is the basis for the successful initiation of the infection cycle of this virus - forms the molecular principle of the VERB Platform developed by Covirabio. A capture matrix has been developed which selectively binds infectious virus particles via ACE2 immobilized on a solid-phase matrix (magnetic bead). Specifically captured intact SARS-CoV-2 particles can be subsequently detected by conventional methods such as RT-qPCR or virus antigen tests and thus the detection can be integrated into existing processes by implementing a simple virus capture step into existing protocols.
The VERB kit makes use of the easy and efficient collection of beads in magnetic field to facilitate SARS-CoV-2 research in a simple workflow of “bind-wash-elute”, which enables to first conduct feasibility studies in manual mode, and then run high-throughput studies in automatic mode.
We are proud to have joined the BioNanoNet association as a standard member, which is operated by BNN - BioNanoNet Forschungsgesellschaft mbH! The BioNanoNet association is a non-profit research organization that aims to strengthen innovative research by fostering collaborations and creating synergies between people working in Health & Safety, Data & Sustainability and Enabling Technologies.
We look forward to benefiting from the extensive expertise of this network, making contacts with like-minded organizations, and receiving support with project applications and project implementation, among other things.